Ryan Fischer's Blog – April 2015 Archive (2)
BioMarin Update
BioMarin has provided the following update on redosing of drisapersen for a new clinical trial. Ambulation will not be an inclusion or exclusion criterion for enrollment, but boys will need to have been previously dosed as part of a clinical trial.
BioMarin Update on Duchenne Muscular Dystrophy…
Added by Ryan Fischer on April 14, 2015 at 9:00am — No Comments
Sarepta Update
Earlier this month Sarepta announced a change in leadership, with CMO Ed Kaye taking over as interim CEO.
Following that announcement the team at Sarepta organized a call with Duchenne patient organizations and foundations to update them…
Added by Ryan Fischer on April 13, 2015 at 11:00am — No Comments
Latest Blog Posts
- 70 Members of Congress Send Letter of Strong Support for Duchenne Priorities for Next Year’s Budget
- End Duchenne Tour Recap: Grand Rapids, MI
- ADD YOUR VOICE: Participate in PPMD’s Gene Therapy Survey
- End Duchenne Tour Recap: Morristown, NJ
- PPMD's 2018 Advocacy Conference | Schedule of Events
- VIDEO: Fundamentals of Access to Duchenne Therapies
- PPMD’s #EverySingleOne Tour: Boston, MA
Most Popular Blog Posts
- ACTION ALERT: Urge Lawmakers to Keep Driving Progress in the Fight to End Duchenne
- One week away from World Duchenne Awareness Day!
- Important Updates on the Duchenne Policy Forum
- ACTION ALERT: Urge House Member - Apply FDASIA Tools to Duchenne
- CALLING ALL CALIFORNIA RESIDENTS!
- ACTION ALERT: Please urge Your Senators to Sign Letter to FDA – Applying FDASIA Tools to Duchenne
- Help Protect Federal Spending on Rare Diseases like Duchenne
© 2021 Created by PPMD.
Powered by
Badges | Report an Issue | Privacy Policy | Terms of Service
